TABLE 1.
Baseline characteristics of analyzed isolates of Enterococcus faecium and Staphylococcus aureus from patients with bloodstream infections.
| E. faecium | S. aureus | |||
| Number of isolates (%) | 55,074 | (100) | 211,379 | (100) |
| Number of isolates tested against linezolid (% tested) | 43,406 | (78.8) | 165,461 | (78.3) |
| Number of isolates tested against daptomycin (% tested) | – | 44,197 | (20.9) | |
| Number of VREF/MRSA isolates (%*) | 6949 | (13.1*) | 35,131 | (17.3*) |
| Year of sampling | ||||
| 2014 (n, %) | 8319 | (15.1) | 32,741 | (15.5) |
| 2015 (n, %) | 9155 | (16.6) | 36,846 | (17.4) |
| 2016 (n, %) | 12,069 | (21.9) | 45,312 | (21,4) |
| 2017 (n, %) | 12,089 | (22.0) | 46,759 | (22.1) |
| 2018 (n, %) | 13,442 | (24.4) | 49,721 | (23.5) |
| European regions | ||||
| North (n, %) | 14,237 | (25.9) | 35,644 | (16.9) |
| West (n, %) | 20,593 | (37.4) | 101,500 | (48.0) |
| South (n, %) | 15,278 | (27.7) | 61,976 | (29.3) |
| East (n, %) | 4966 | (9.0) | 12,259 | (5.8) |
| Gender of patients | ||||
| Female (n, %) | 19,785 | (32.8) | 74,006 | (35.0) |
| Male (n, %) | 30,695 | (58.8) | 121,780 | (57.6) |
| NA (n, %) | 4594 | (8.5) | 15,593 | (7.4) |
| Sex ratio (f/m) | 0.64 | 0.61 | ||
| Age of patients | ||||
| <1 year (n, %) | 562 | (1.0) | 4389 | (2.1) |
| 1–19 years (n, %) | 721 | (1.3) | 6005 | (2.8) |
| 20–59 years (n, %) | 16,850 | (30.6) | 65,176 | (30.8) |
| ≥65 years (n, %) | 33,502 | (60.8) | 125,486 | (59.4) |
| NA (n, %) | 3439 | (6.2) | 10,323 | (4.9) |
| Age (median, IQR) | 70yrs | 60–79 years | 70yrs | 57–80 years |
| Hospital unit type | ||||
| Intensive care unit | 13,606 | (24.7) | 26,965 | (12.8) |
| Non-intensive care unit | 30,802 | (55.9) | 153,855 | (72.8) |
| NA (n, %) | 10,666 | (19.4) | 30,559 | (14.5) |
| Number of hospitals | 1873 | 1955 |
E. faecium, Enterococcus faecium; IQR, Interquartile range; MRSA,: Methicillin-resistant Staphylococcus aureus, S. aureus, Staphylococcus aureus; VREF, vancomycin-resistant Enterococcus faecium proportion.